Hormonal therapies up-regulate MANF and overcome female susceptibility to immune checkpoint inhibitor myocarditis
Male
0301 basic medicine
Cardiovascular
Medical and Health Sciences
Mice
03 medical and health sciences
2.1 Biological and endogenous factors
Humans
Animals
Estrogen Receptor beta
Myocytes, Cardiac
Nerve Growth Factors
Aetiology
Immune Checkpoint Inhibitors
Myocytes
Estradiol
Biological Sciences
Estrogen
3. Good health
[SDV] Life Sciences [q-bio]
Myocarditis
Heart Disease
5.1 Pharmaceuticals
Female
Development of treatments and therapeutic interventions
Cardiac
DOI:
10.1126/scitranslmed.abo1981
Publication Date:
2022-11-02T17:58:46Z
AUTHORS (31)
ABSTRACT
Immune checkpoint inhibitors (ICIs) have been increasingly used in combination for cancer treatment but are associated with myocarditis. Here, we report that tumor-bearing mice exhibited response to combinatorial anti–programmed cell death 1 and anti–cytotoxic T lymphocyte antigen–4 antibodies also presented cardiovascular toxicities observed clinically ICI therapy, including myocarditis arrhythmia. Female were preferentially affected compared male mice, consistent a previously described genetic model of emerging clinical data. Mechanistically, myocardial tissue from ICI-treated the mouse model, human heart patients all down-regulation MANF (mesencephalic astrocyte–derived neurotrophic factor) HSPA5 (heat shock 70-kDa protein 5) heart; this was particularly notable female mice. amplified by heart-specific deletion Manf attenuated administration recombinant protein, suggesting causal role. Ironically, both transcriptionally induced liganded estrogen receptor β inhibited androgen receptor. However, reduced serum estradiol concentration greater extent Treatment an β–specific agonist depletion therapy ICI-associated cardiac effects. Together, our data suggest inhibits estradiol-dependent expression MANF/HSPA5 heart, curtailing cardiomyocyte immune injury. This endocrine-cardiac-immune pathway offers new insights into mechanisms sex differences disease may offer strategies
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (75)
CITATIONS (37)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....